跳至主要内容
临床试验/ISRCTN81414657
ISRCTN81414657已完成3 期

ow-dose aspirin in the prevention of preeclampsia: a randomised control study

Beacon Pharmaceuticals Ltd0 个研究点目标入组 200 人开始时间: 2022年5月19日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
Female

入选标准

  • Current inclusion criteria as of 26/05/2022:
  • 1. Maternal age =18 years
  • 2. Live foetus at gestational age 12–19 weeks
  • 3. Any one of the following criteria:
  • 3.1. BMI =30 kg/m2
  • 3.2. Pregnancy interval >10 years
  • 3.3. Multiple pregnancy
  • 3.4. Pregnancy assisted by ovulation-inducing drugs/in vitro fertilization
  • 3.5. Pregnant women with medical disorders, e.g. chronic hypertension, hyperglycaemia in pregnancy, autoimmune disease (e.g. antiphospholipid syndrome [APS], systemic lupus erythematosus [SLE])
  • 3.6. Previous history of gestational hypertension, pre-eclampsia or eclampsia
  • 3.7. Previous history of intrauterine growth restriction (IUGR), intrauterine death or stillbirth
  • 3.8. Family history (mother and/or sister) of hypertension, gestational hypertension or pre-eclampsia
  • Previous inclusion criteria:
  • 1. Nulliparous
  • 2. Maternal age =16 years and =35 years
  • 3. BMI =30 kg/m²
  • 4. Live foetus at gestational age 12 weeks – 19 weeks
  • 5. Pregnancy interval >10 years
  • 6. Multiple pregnancy
  • 7. Pregnancy assisted by ovulation-inducing drugs/in vitro fertilization
  • 8. Pregnant women with medical disorders: chronic HTN, hyperglycaemia in pregnancy, thyroid disorder, autoimmune disease - antiphospholipid syndrome (APS), systemic lupus erythematosus (SLE)
  • 9. Previous history of gestational HTN, preeclampsia (PE), eclampsia
  • 10. Previous history of intrauterine growth restriction (IUGR), IUD, stillbirth
  • 11. Family history of HTN, gestational HTN, PE (mother and/or sister)

排除标准

  • Current exclusion criteria as of 26/05/2022:
  • 1. Allergic to aspirin
  • 2. Peptic ulcer disease
  • 3. Mental disease
  • 4. Treatment with antifolate drugs (antiepileptics, methotrexate)
  • 5. Patient will not give consent to participate
  • Previous exclusion criteria:
  • 1. Allergic to aspirin
  • 2. Peptic ulcer disease
  • 3. Pregnant women who are at risk of developing PE but who have renal failure, hepatic failure, cardiac failure and hematological disorder
  • 4. Mental disease
  • 5. Treatment with antifolate drugs (antiepileptics, methotrexate)
  • 6. Patient will not give consent to participate

研究者

发起方
Beacon Pharmaceuticals Ltd

相似试验